Nephrotic syndrome with acute kidney injury induced by cetuximab
10.3760/cma.j.cn114015-20240731-00661
- VernacularTitle:西妥昔单抗致肾病综合征合并急性肾损伤
- Author:
Lei SUN
1
;
Jie NING
;
Fang WANG
;
Jing RAO
;
Jiemei JIANG
Author Information
1. 淮南东方医院集团总医院药学部，淮南 232033
- Publication Type:Journal Article
- Keywords:
Sigmoid neoplasms;
Nephrotic syndrome;
Acute kidney injury;
Albuminuria;
Cetuximab
- From:
Adverse Drug Reactions Journal
2025;27(11):694-696
- CountryChina
- Language:Chinese
-
Abstract:
A 59-year-old male patient with sigmoid colon cancer and liver metastasis received the treatments of cetuximab combined with FOLFIRI regimen (irinotecan, calcium folinate, and fluorouracil). His serum creatinine (Scr) was 82 μmol/L, and estimated glomerular filtration rate (eGFR) was 96 ml/(min·1.73 m 2) before the treatment. On the 11th day after finishing the 4th cycle of treatments, the patient developed nausea and vomiting. Laboratory tests showed Scr 221 μmol/L, eGFR 29 ml/(min·1.73 m 2), serum albumin 29.0 g/L, urinary protein (+++), and 24 hour urine protein quantified 8.88 g. He was diagnosed as having nephrotic syndrome complicated with acute kidney injury, which was considered to be related to cetuximab. The drug was stopped and symptomatic treatments such as anti-inflammatory, anticoagulation and kidney protection were given. After 14 days, laboratory tests showed no proteinuria, Scr 156 μmol/L, and eGFR 44 ml/(min·1.73 m 2). Prednisone acetate tablet 50 mg were orally administered once daily. Fifty-nine days later, his Scr was 142 μmol/L, and eGFR was 49 ml/(min·1.73 m 2). Chemotherapy was suspended and cetuximab was discontinued permanently.
